Fortis Shares Slip 5% to ₹836 as Supreme Court Greenlights Forensic Audit

The market’s reaction was immediate and sharp. Fortis Healthcare (NSE: FORTIS) closed nearly 5% lower at ₹836 on Friday, September 27, capping a turbulent month where the stock has shed approximately 10% of its value. The sell-off was triggered by the Supreme Court’s decision to allow a forensic audit of the company to proceed, a move that had been pending since the Delhi High Court’s directive on August 31, 2026.

This isn’t a condemnation, but it keeps the overhang alive. The Supreme Court clarified that the Delhi High Court’s observations were limited strictly to the procedural question of whether the audit should happen, not a final judgment on liability. Fortis Healthcare stated in a regulatory filing that no liability, penalty, or fine has been imposed on the company as part of these proceedings. For now, the balance sheet remains untouched by direct financial penalties, but the uncertainty is priced in.

The company is pushing back hard on the narrative linking it to the dispute between Daiichi Sankyo and the Singh brothers. Fortis emphasized it is not a party to that arbitration. It further noted that it had no control over share transfers when the Singh brothers were owners and that the transaction with IHH Healthcare occurred only after their association with the company had ended. This distinction is vital for institutional investors trying to gauge legal exposure versus operational stability.

With the audit now underway, attention shifts to what the forensic accountants uncover. The stock’s 10% slide over the past month suggests traders are de-risking ahead of any potential findings. Keep an eye on the next quarterly results and any further interim orders from the courts, as the forensic audit could take months to conclude. Until then, the 5% drop on Friday looks like the start of a longer consolidation phase rather than a capitulation.